A carregar...
Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes
Cytarabine resistance characterizes relapsed and refractory acute myelogenous leukemia (AML). Restoration of cytarabine sensitivity can potentially improve treatment outcome in this setting. Acquired hypermethylation of gene promoters and associated silencing of gene expression has been implicated i...
Na minha lista:
| Main Authors: | , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2010
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2876330/ https://ncbi.nlm.nih.gov/pubmed/20017599 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428190903318329 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|